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Abstract
Dengue viruses (DENV) are enveloped single-stranded positive-sense RNA viruses transmitted by Aedes spp. mosquitoes.
There are four genetically distinct serotypes designated DENV-1 through DENV-4, each further subdivided into distinct
genotypes. The dengue scientific community has long contended that infection with one serotype confers lifelong
protection against subsequent infection with the same serotype, irrespective of virus genotype. However this hypothesis is
under increased scrutiny and the role of DENV genotypic variation in protection from repeated infection is less certain. As
dengue vaccine trials move increasingly into field-testing, there is an urgent need to develop tools to better define the role
of genotypic variation in DENV infection and immunity. To better understand genotypic variation in DENV-3 neutralization
and protection, we designed and constructed a panel of isogenic, recombinant DENV-3 infectious clones, each expressing
an envelope glycoprotein from a different DENV-3 genotype; Philippines 1982 (genotype I), Thailand 1995 (genotype II), Sri
Lanka 1989 and Cuba 2002 (genotype III) and Puerto Rico 1977 (genotype IV). We used the panel to explore how natural
envelope variation influences DENV-polyclonal serum interactions. When the recombinant viruses were tested in
neutralization assays using immune sera from primary DENV infections, neutralization titers varied by as much as ,19-fold,
depending on the expressed envelope glycoprotein. The observed variability in neutralization titers suggests that relatively
few residue changes in the E glycoprotein may have significant effects on DENV specific humoral immunity and influence
antibody mediated protection or disease enhancement in the setting of both natural infection and vaccination. These
genotypic differences are also likely to be important in temporal and spatial microevolution of DENV-3 in the background of
heterotypic neutralization. The recombinant and synthetic tools described here are valuable for testing hypotheses on
genetic determinants of DENV-3 immunopathogenesis.
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Introduction
Dengue virus (DENV)is anenveloped (+) RNA virus inthe family
Flaviviridae, genus Flavivirus transmitted by the bite of Aedes spp.
mosquitoes. DENV occurs throughout the tropics and subtropics
and infects approximately 50 million individuals annually. There
are four distinct serotypes, DENV-1–DENV-4. While prospective
studies have found that most infections are asymptomatic, a
proportion of infected persons will develop symptoms that include
fever, rash and myalgia [1,2] with 2% or less developing the severe
disease syndromes of dengue hemorrhagic fever/dengue shock
syndrome (DHF/DSS) [2], characterized by hemorrhage, vascular
leakage,hypovolemia and,if untreated, shock, end organ failureand
death [3]. Approximately 15,000–30,000 persons die annually from
DHF [1]. DHF/DSS has been classically associated with secondary
infections that occur in the context of pre-existing heterotypic
immunity - leading to hypotheses that DHF/DSS is an immune
mediated phenomenon driven by cross-reactive DENV antibodies
and/oror DENVspecific CD8+ T-cells (forreviews see: [4,5]. Virus
genotype also clearly plays an important role in severe disease
pathogenesis, as. Multiple studies of DENV molecular epidemiology
have found associations between circulating virus genotype and
disease severity [6–12]. However, the genetic basis of these virulence
differences has not been deciphered.
One of the fundamental barriers to DENV vaccine development
has been concern that a DENV vaccine must be broadly protective
againstallfourserotypesorrecipientswillrisksecondary-likeinfection
and the severe disease associated with naturally acquired secondary
infection. Most vaccine trials have assessed protection against all four
serotypes using prototype or vaccine related virus isolates [13] and
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8studies need to address the degree to which intra-serotype genotypic
differences may affect antibody-mediated immunity to any of
the DENV serotypes, including DENV-3. While genotype specific
genetic differences are scattered across the viral genome, the envelope
glycoprotein (E) is the main target of neutralizing human antibody
and is one logical first choice for assessing the genetic basis of
differential antibody mediated neutralization of DENV-3 infection.
The E glycoprotein exists as a homo-dimer with 3 distinct domains –
I, II, and III [14–17], that, on the mature DENV virion, are arranged
in a flat herringbone pattern with icosahedral symmetry [14].
Domains I (EDI) and II (EDII) are linearly discontinuous and fold to
form a central eight-stranded ß barrel (domain I) with a lateral
protrusion (domain II) that contains the highly conserved fusion loop
required for virion fusion with endosomes. Domain III (EDIII) is a
continuous peptide that extends from domain I and forms an Ig like
fold that is believed to be the ligand for an as yet unidentified cellular
receptor.
A successful dengue vaccine should induce broadly protective
antibodies against all geographic variants of each serotype. The
dengue community has long held that primary infection with one
serotype confers long-lasting immunity to that serotype, irrespective
of the infecting virus genotype. This is based principally on early
human challenge trials [18] and multiple observational studies that
have shown that, within a particular region, re-infection with the
same serotype generally does not occur. Geographic partitioning of
DENV genotypes significantly limits our understanding of the role
of strain variation in protective immunity, as the vast majority of
DENV infected persons in endemic regions never travel to regions
where other DENV genotypes are circulating. Several recent
findings indicate that genotypic variation may be important in
immunity. Recent studies of DENV-3 strain variants using
recombinant proteins and whole virus have found that neutraliza-
tion mAbs raised against one DENV-3 genotype have limited
neutralization activity against heterologous genotypes [19–22].
After primate vaccination, studies with polyclonal immune sera
have also demonstrated variable neutralization of DENV3 strains
[23]. In a study of pediatric dengue cases in Thailand, investigators
observed significant differences in the ability of sera to neutralize
referenceandclinicalstrainsofDENV3[24].ArecentWHOreport
on dengue neutralization testing highlighted the need for evaluating
vaccine induced immune responses using contemporary strains
representing the different serotypes and genotypes of dengue [25].
DENV-3 consists of four distinct genotypes: I, II, III and IV,
each originally associated with a specific geographic region [26].
Currently genotype I and II are circulating in Asia, genotype III is
circulating in the Indian subcontinent, Africa and Latin America,
and genotype IV appears to have been displaced but occurred
throughout the Caribbean in the 1960s and 70s [7,26–31]. Here
we described the construction of a four-fragment DENV-3 infec-
tious clone platform and a panel of isogenic DENV-3 recombinant
viruses that captures DENV-3 E glycoprotein genotypic hetero-
geneity. While our approach is novel for flaviviruses, human
coronavirus (CoV) investigators have used a similar system to
introduce large, synthesized genomic elements into recombinant
viruses to investigate genetic variability in CoV biology and
pathogenesis (see [32–35] for examples). The CoV systems are a
powerful tool for expanding understanding of genetic differences
in CoVs and the application to Flaviviruses may prove similarly
powerful. We subsequently tested the isogenic recombinant viruses
against a panel of immune sera from people exposed to primary or
secondary DENV infections. These data demonstrate a role for
natural epitope variation in virus neutralization and escape. The
molecular clone should also prove to be a valuable tool for
studying a variety of other aspects of DENV-3 biology, patho-
genesis, immunopathogenesis, epitope mapping and evolution.
Materials and Methods
Ethical Statement
The Institutional Review Board of the University of North
Carolina at Chapel Hill approved the protocol for recruiting and
collecting blood samples from people. Written informed consent
was obtained from all donors.
Tissue Culture
Vero E6 cells (ATCC CRL-1586) were maintained in MEM
supplemented with 10% FCS (Gibco), non-essential amino acids
(Gibco), L-glutamine (Gibco) and Anti-Anti antibiotic mix (Gibco)
at 37uCi n5 %C O 2. C6/36 cells (ATCC CRL-1660) were
maintained in MEM supplemented with 5% FCS, non-essential
amino acids, L-glutamine and Anti-Anti at 28uCi n5 %C O 2.
DENV3 Molecular Clone Strategy
The cloning strategy for the DENV-3 clone is illustrated in
F i g u r e1 A ,a n db a s e do ns t r a t e g i e se m p l o y e dw i t hC o V st o
circumvent sequence instability problems in E.coli [36,37]. The clone
parent is a 1989 Sri Lankan DENV3 isolate (genotype III) designated
UNC3001 (submitted to GenBank). To isolate the DENV-3 sub-
clones, reverse transcription was performed with AMV reverse
transcriptase (Roche) and oligodeoxynucleotide primers according to
the manufacturer’s recommendations using primer BsmbIDen.
Following cDNA synthesis, the cDNA was amplified by PCR with
Expand Long TAQ polymerase (Boehringer Mannheim Biochem-
ical) with cycle settings based on the size of the amplicon. The
Dengue genome was amplified from cDNA and cloned as a set of
four fragments (Figure 1 and Text S1). The first fragment, A, was
PCR amplified using primer set DEN#1a n dD E N 2 k b 2.T h e s e
primers created a T7 RNA promoter at the 59 end of the fragment
and a BsmBI restriction site at its 39 end, respectively. The PCR
product was gel isolated (Qiagen QIAquick Gel Extraction Kit) and
then cloned into the pCR-XL TOPO cloning vector (Invitrogen).
Author Summary
Infectious virus clones are valuable tools for studying how
changes in viral genetic codes affect viral biology. Dengue
virus is the most important mosquito-borne virus world-
wide, yet dengue virus infectious clones have historically
been challenging to make and manipulate, making it very
difficult to study the variety of genetic changes observed
in dengue viruses. Here we describe the construction of a
panel of five dengue virus serotype 3 (DENV-3) clones
using a novel strategy not previously employed in dengue
research. This strategy uses genetic fragments and
synthesized genes to introduce genetic changes while
minimally affecting the virus. Each of the five recombinant
clones was designed to express genetically distinct DENV-3
envelope proteins derived from strains circulating in
different regions of the world. We used the recombinant
viruses, coupled with DENV-3 sera from geographically
defined human cases, to study the impact of E variation on
neutralization outcomes. Our data demonstrate that the
recombinant viruses varied significantly in their neutrali-
zation outcomes, depending on sera. While it has long
been presumed that infection, and vaccination, with one
serotype confers lifelong protection against all variants of
that serotype, our results indicate that this assumption
requires a more rigorous assessment by the DENV
community.
Variable Neutralization of DENV3 Genotypes
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and DENBGL42. The DEN2kb+ primer introduced a BsmBI site
that allowed for the directional ligation of fragments A and B
(Figure 1 and Text S1). The DENBGL42 primer introduced
silent changes in the Dengue genome between nucleotides (nt)
3150 and 3160 to create a unique BglI site without altering the
amino acid sequence. Fragment C was amplified with primers
DENBLG3+ and DEN7kb2. This primer set duplicated the BglI
site at the 39end of the B fragment and a naturally occurring BglI
site at nt 7031. The PCR amplicons for both fragments B and C
were gel isolated and cloned into the pCR-XL TOPO cloning
vector.
Fragment D was amplified with primers DEN5kb+ and
BsmBIDen. This PCR product, which went from approximately
nt 5100 to the 39 end of the Dengue genome, contained two BglI
sites; one at nt 7032 and the other at nt 10186. The BglI site at nt
10186 was removed using overlapping PCR. Two amplicons – 39
and 59, were generated using primers Dengue15 and Den10198
and primers Den10166 and BsmBIDen, respectively. These two
amplicons were joined in an over-lapping extension PCR reaction.
The resulting product was digested with SapI and ligated to SapI
digested DEN D fragment. This final cDNA fragment, which now
had the BglI site at 10186 knocked out, was gel isolated and cloned
into the Big Easy v2.0 Linear cloning vector (Lucigen).
Four to six clones of each fragment were sequence verified. The
four DEN cDNAs were isolated from plasmids and directionally
ligated to create a full-length cDNA of the dengue viral genome.
This full-length cDNA contained only the introduced nucleotide
changes, all of which were silent, and could be transcribed with T7
polymerase (Ambion). This RNA produced infectious dengue virus
when electroporated into Vero E6 cells.
To construct E glycoprotein variant clones (Figure 1B), synthe-
sized envelope genes (nucleotides 913–2416 of the Dengue genome)
were delivered in puc57 plasmids (Bio Basic). The portion of these
envelope genes that needed to be inserted into the A plasmid, was
PCR amplified with either a puc57 forward or reverse primer and
the Den2kb2 primer (Text S1). These products were digested with
BstEII and BsmBI and ligated into the A plasmid which had been
digested with the same enzymes. Dengue B plasmids containing the
envelope variants were generated by first PCR amplifying the
synthetic genes with the Den 2kb+ primer and primer EGENE2
(Text S1) and the parent B fragment with primer EGENE+ and
DENBGL42 (Text S1). These products were then digested with
BsaI and ligated together. Finally, the ligations were gel purified and
cloned into the pCR-XL TOPO cloning vector.
To replace the parent clone prM/M gene with a genotype I
prM/M gene, RNA from our lab stock genotype I virus UNC3043,
was reverse transcribed with random hexamers and the cDNA was
PCR amplified with primers Dengue01+ and Denv900. The
resulting amplicon was digested with BstAPI and PflMI. This
product was ligated into the DEN A plasmid corresponding to the
Indonesia 1982 genotype I E gene that had been digested using the
same enzymes. The resulting plasmid DEN A was sequence verified
and used to construct the genotype I recombinant virus.
Recombinant Virus Recovery
Each plasmid was transformed and propagated in E. coli
TOP10 competent cells (Invitrogen) and grown on LB plates with
selective antibiotics (A, B, and C containing plasmids selected with
kanamycin, D with chloramphenicol) at 28.5uC for 24 hours.
Individual colonies were picked, screened and sequenced. The
plasmidsweresubsequentlygrown to high concentrationinselective
LB, plasmid purified (Qiagen Mini-Spin Kit) and digested as follows
according to manufacturers instructions: DEN A with SpeI (NEB)
followed by calf intestine phosphotase (NEB) and BsmBI (NEB)
yielding a 2.0 kb fragment; DEN B with BglI (NEB) and BsmbI
yielding a 1.1 kb fragment; DEN C with BglI yielding a 3.9 kb
fragment; and DEN D with BglI and BsmbI yielding a 3.0 kb
fragment. Fragments were gel-isolated (Qiagen Gel Extraction Kit)
on 0.8% agarose gel, mixed in equivalent copy number and ligated
with T4 ligase (NEB) overnight at 4uC. Full-length transcripts of
DENV-3 cDNA constructs were generated in vitro as described by
the manufacturer (Ambion, Austin, Tex; mMessage mMachine)
with the following modifications: For 30-ml reaction mixtures
supplemented with 4.5 ml of a 30 mM GTP stock, resulting in a 1:1
ratio ofGTPto capanalog and incubated at 37uC for2 hours.Vero
cells weregrown to 75% confluence, trypsinized and resuspended in
RNAse free PBS at 10
7 cells/ml. RNA transcripts were mixed with
800 ml ofthe Vero cell suspension inan electroporation cuvette, and
four electrical pulses of 450 V at 50 mF were given with a Bio-Rad
Gene Pulser II electroporator. The transfected Vero cells were
seeded at 5610
6/ml in 75-cm2 flask and incubated at 37uC for 4
days. Two to five ml of supernatant from electroporated Vero cells
were passaged on day 4 to 75% confluent uninfected Vero cells in a
75 cm
2 flask. Fresh media was added to a final volume of 15 ml.
Seven day supernatants were harvested, supplemented to 30% FBS,
clarified by centrifugation and frozen at 280uC or passaged serially
to amplify a working virus stock.
Envelope Gene Design
At the time this study was initiated, there were 164 unique, full-
length DENV-3 envelope genes available in Genbank, and these
sequences were added to 11 Sri Lankan DENV-3 sequences from
our laboratory. The 175 envelope amino acid sequences were
aligned using ClustalX version 1.83 [38], and one representative
sequence was selected for each DENV-3 genotype. The represen-
tative sequence was chosen based on amino acid conservation
Figure 1. Design of DENV3 infectious clone and chimeras. Panel A provides a schematic representation of the DENV genome, divided into
structural and nonstructural genes. Arrows indicate primer name and approximate primer locations and orientation on the genome. These primers
were used to amplify the different cDNA fragments as well as adding appropriate, terminal restriction enzyme recognition sequences. The T7
promoter is located at the 59end of primer DEN#1. Primer pairs that generate complete fragments are aligned opposite one another. The clone was
propagated in in three circular and one linear plasmid. DENV fragments within each plasmid are highlighted in blue. The final fragments assembled
to generate the clone are represented at the bottom of the figure as blue lines. Lengths and restriction site locations are approximate and supported
by exact primer sequences, positions and PCR fragment sizes as noted in Text S1. Panel B illustrates the strategy used for E gene construct insertion.
The top figures represent the DEN A and B fragments, which encode for the E protein. Arrows indicate approximate locations of primers EGENE+ and
EGENE2 used to silently introduce a BsaI recognition sequence into the 59 end of fragment DEN B. The Bio Basic E construct in black represents the
synthesized E gene, and the schematic below it illustrates approximate arrangement of E gene domains and restriction sites. Roman numerals
indicate E domains; TM=transmembrane region. Arrows indicate primer names, approximate location and pair orientation used to introduce
restriction enzyme recognition sequences Lengths and positions shown are approximate. The E construct is amplified for insertion into the DEN A
fragment with primers pUC57 and with DEN2kb2 and for the B fragment with primers DEN2kb+ and EGENE2. After sequence confirmation,
constructs and DEN A and B fragments are digested with indicated enzymes, desired fragments gel purified and subjected to ligation to generate
new DEN A and DEN B fragments containing E constructs. *Type IIS restriction endonuclease.
doi:10.1371/journal.pntd.0001486.g001
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with no outlier amino acids selected as the representative.
Representative sequences chosen were: Genotype I Indonesia
1982 (GenBank accession# DQ401690.1); Genotype II Thailand
1995 (GenBank accession# AY676376); Genotype III Cuba 2002
(GenBank accession# AY02031); and Puerto Rico (PR) 1977
(GenBank accession# AY146761). All viruses used in the sub-
sequent experiments were passage three propagated in Vero cells.
All passage three clones were sequence verified using previously
described methods [39].
Growth Curves
To assess viral replication kinetics, each of the DENV-3 clones
was inoculated in triplicate onto 95% confluent monolayers of
Vero or C6/36 cells in 6 well plates at a multiplicity of infection
(m.o.i) of 0.01 ffu/ml. Cells were incubated at either 37uC for
Vero or 27uC for C6/36 cells under maintenance media
conditions for the cell line for 60 minutes, after which the
innocula were removed and cells washed twice in 3 ml of PBS.
Each monolayer was covered in a total volume of 5 ml media.
After 60 min, 200 ul of cell supernatant, designated as the Day 0
sample, was taken in duplicate with equal volume media replaced.
Samples were supplemented with 30% FCS, clarified by
centrifugation and stored at 280uC. Samples were taken in the
same manner every 24-hrs for 6 additional days. Virus titers were
determined as described below.
Primary and Secondary Sera
Sera were collected from adult volunteers with histories of
DENV infection [40] and one anonymous donor with dengue
infection confirmed by serology (sample 109). Sera were
characterized by flow cytometry at UNC [41], PRNT60 at the
NIH, Bethesda, MD, or PRNT90 at CDC San Juan to confirm
past exposure to primary or secondary DENV infections and also
to identify the serotype responsible for primary infections. We note
that we cannot establish the infecting virus genotype of our
experimental sera on neutralization patterns alone. However, only
genotypes I, II, and III are currently circulating, and our samples
almost certainly capture genotype II (Thailand) and III (Latin
America) based on donor travel history.
Virus Titration and Focus Reduction Neutralization Test
(FRNT)
The FRNT procedure is based on a method previously
described by Whitehead [42]. Briefly, twenty-four well plates
were seeded with 5610
4 Vero cells in MEM supplemented with
5% fetal bovine serum (FBS) and grown for 24 hours. Growth
media was removed. For virus titration, virus stocks were diluted
serially ten-fold from 10
21 to 10
26 and 200 ul of each dilution
added to individual wells. After 1 hr incubation on a rocker at
37uC, the wells were overlaid with 1 ml 0.8% methylcellulose in
OptiMEM (Gibco) supplemented with 2% FBS (Cellgro) and
antibiotic mix (Gibco Anti-Anti). Plates were incubated 5 days at
37uC, 5% CO2. On day 5, overlay was removed, cells washed with
PBS, fixed in 80% methanol and either stored at 280uCo r
developed. To develop plates, fixed monolayers were blocked for
10 minutes with 5% instant milk PBS, followed by incubation with
anti-flavivirus MAb 4G2 diluted 1:1000 in blocking buffer for 1 hr
at 37uC. Wells were washed with PBS and incubated with
horseradish peroxidase (HRP) conjugated goat anti-mouse Ab
(Sigma) diluted 1:500 in blocking buffer for 1 hr at 37uC. Plates
were washed once in PBS and foci developed by the addition of
100 ul of TrueBlue HRP substrate (KPL). Foci were counted on a
light box and viral titers calculated by standard methods. For
FRNT, MAbs or human sera were serially diluted five-fold from
starting dilutions of 1:5 or 1:10. Each dilution was mixed with
approximately 30 focus forming units (ffu) of virus to a final
volume of 200 ul, incubated for 1 hour at 37uC, 5% CO2 and
added in triplicate to 24 wells plates and processed as above. Mean
focus diameter was calculated from $20 foci/clone measured at
56magnification.
Software and Statistics
Multiple alignments were performed using ClustalX version
1.83 [38] and phylogenetic trees of the envelope protein sequences
were conducted using Mr. Bayes version 3.12 (Huelsenbeck JP,
2001). Briefly, 175 amino acid envelope sequences were imported
into ClustalX and the alignment was performed using default
parameters. Structural models of the informative sites were
generated using MacPymol (Delano Scientific) and the crystal
structure of DENV-3 envelope (PDB 1UZG) [16]. Mean focus
sizes were compared by one-way analysis of variance (ANOVA)
followed by Dunnett’s test for multiple comparisons. Growth curve
and FRNT counts were entered into Graphpad Prism (Version
5.00 for OSX, GraphPad Software, San Diego California USA,
www.graphpad.com). FRNT50 values were calculated by sigmoid
dose-response curve fitting with upper and lower limits of 100 and
0 respectively. All error bars show 95% confidence intervals unless
otherwise specified. Mean FRNT50 values were compared by one-
way ANOVA followed by Tukey HSD multiple comparison test
with significance level alpha (P) set at ,0.05.
Results
Construction of the Parent and Isogenic Envelope
Glycoprotein (E) Variant Clones
The parent DENV-3 clone is a genotype III variant isolated
from a Sri Lankan DF patient in 1989 (Figure 2) (See materials
and methods). Full-length flaviviruses genomes have been
previously described as unstable and toxic in traditional E. coli
clone systems [43–46]. To disrupt the putative toxic regions and
facilitate creation of chimeric DENV-3 clones, the genome was
cloned into segmented, sequential fragments. The fragments and
junctions in the final platform were chosen to through multiple
trials to maximize insert and plasmid stability in E. coli. Clone
junctions were based on type IIS restriction enzyme sites (BsmBI
and BglI) (Figure 1A) that allow directional assembly into full-
length cDNAs as described in Materials and Methods. After
digestion and purification of individual cDNAs, the full-length
cDNA was assembled by in-vitro ligation, transcripts were
electroporated into cells and recombinant viruses were recovered
from first passage Vero cell culture supernatant. Sequence analyses
verified indicator mutations within the cDNA clone fragments and
no nucleotide mutations were detected in the entire genome of the
recombinant virus after three passages in Vero cells (data not
shown).
To evaluate the role of DENV3 E protein sequence variation on
antibody interactions, representative E genes from genotype I, II,
III and IV viruses (Figure 2, Text S1) were selected from 175
published DENV-3 sequences. Each E gene was selected to
represent a genotype whose sequence most closely matched a
consensus E sequence generated for each genotype. Genotype I is
a 1982 Indonesia isolate, genotype II is a 1995 Thailand isolate,
genotype III a 2002 Cuba isolate, and genotype IV a 1977 Puerto
Rico isolate. A total of 32 informative sites were identified across
the representative genotypes (Materials and Methods), forming
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distributed through domains I, II and III (Text S1).
To generate clones that would allow testing of variable
neutralization, these representative sequences were synthesized
by Bio Basic and inserted into the parent clone background,
replacing the parent E gene (Figure 1B). Three of the four variant
clones were successfully recovered with correct replacement of the
E gene alone. One variant, however, Indonesia ’82 (genotype I),
required the replacement of the parent SL ’89 genotype III preM/
M gene with a genotype I preM/M gene, supporting earlier
studies that co-evolutionary changes in preM/M may be essential
for efficient E gene function in select instances [47]. Full-length
sequencing of all passage three recombinant virus clones used
throughout these experiences found only one nucleotide mutation
in one of the five clones, a silent C to T pyrimidine transition
mutation at genomic position 7043 in the genotype I virus.
Focus Formation
Because some DENV clinical isolates do not reliably form
plaques on Vero cell monolayers, viral growth on Vero cell
monolayers was instead characterized through focus formation
(see Materials and Methods). All five clones formed foci on Vero
cell monolayers. The parent clone, SL ’89 (III) and Cuba ’02 (III)
produced moderate sized and relatively uniform foci after 5d
growth on a Vero cell monolayer (Table 1). Clones with Indonesia
’82 (I) E genes produced marginally smaller foci, while Thailand
’95 (II) and PR ’77 (IV) foci were markedly smaller than those
formed by the parent clone (Table 1). The striking difference in
plaque phenotype underscores the importance of structural
proteins in basic viral biology, and may be due to either E gene
differences in the virus envelope or prM-E mismatch in the virus
clones, though identifying the particular genetic differences
causing the phenotype is beyond this paper’s scope.
Growth Kinetics
The growth kinetics of the panel of recombinant viruses were
characterized in mammalian Vero cells and C6/36 mosquito cells,
both of which are a commonly used for DENV propagation and
quantification. Both cell lines were infected with the parent and
clones at a multiplicity of infection (MOI) of 0.01 FFU/cell and
grown for 216 hours. In Vero cells, the growth curves for the
parent virus and the five clones were similar, with all preparations
producing focus-forming virus after 24 hours and peak viral titers
achieved between 120 hours and 168 hours (Figure 3A). Peak log
viral titers ranged from 6.68 log FFU/ml for the parent clone to
5.10 log FFU/ml for the genotype II clone. Early growth was
slower in the genotype I Indonesia recombinant virus, but
ultimately reached peak titers equivalent to the other recombi-
nants. Growth kinetics in C6/36 cells were similar to those in Vero
cultures except that virus was not detected until 48 hrs post
infection (Figure 3B). Peak titers were generally similar, though the
parent clone had a single peak log titer of 7.70 log FFU/ml that
was significantly higher than the other virus samples. The
remaining peak titers ranged from 6.30 log FFU/ml to 6.66 log
FFU/ml and did not differ significantly. The genotype I Indonesia
clone did show slower kinetics than the other clones, particularly
early in infection (Figure 3B). Overall, inter-genotypic E variability
had minimal impact on the viruses’ growth in tissue culture.
Human Polyclonal Sera Neutralization
To assess the role of DENV E glycoprotein variation on viral
neutralization by human polyclonal sera, the isogenic clones were
tested against a panel of late convalescent (.2 years) human anti-
DENV primary and secondary sera collected from individuals in
North Carolina who had been infected during foreign travel
[40](Table 2 and Text S1). The majority of the neutralization tests
were repeated in independent experiments, with highly reproduc-
ible FRNT50 values (Text S1). The original infecting virus is not
known for any of these sera.
Eight primary anti-DENV-3 serum samples were tested against
the parent and isogenic recombinant viruses with variable E genes
from the different DENV-3 genotypes (Text S1). The clones did
not show differential neutralization patterns against three of the
sera; 003, 005 and 103 (Figure 4A, B, and E). Serum sample 003
was taken from a traveler who acquired a primary DENV-3
infection in Thailand. FRNT50 titers for 003 ranged from 1:59 for
Cuba’02 (III) to 1:203 for Indonesia ’82 (I) (Text S1). Serum
sample 005 was taken from a traveler who acquired a primary
DENV-3 infection in Puerto Rico. Calculated FRNT50 were
similar to those observed for 003, with titers ranging from a low
titer of 1:31 against PR ’77 (IV) to a high of 1:118 against the Sri
SL ’89 (III) clone and Indonesia ’82 (I) (Text S1). Serum sample
103 was from a traveler infected with DENV-3 in Nicaragua in
1995. FRNT50s ranged from a low 1:42 (PR ’77 (IV)) to a high of
1:117 for Thailand ’95 (II) (Text S1). While these FRNT50 values
are consistent with most accepted cutoffs for true homotypic
neutralization, they are consistently low, with six of the fifteen
clone titers in this group less than 1:60 (Text S1).
More importantly, we found significantly variability neutraliza-
tion profiles against the five recombinant viruses neutralized with
the five remaining homotypic sera tested (Figures 5C, 5D, 5F, 5G
and 5H). Though serum sample 011, from an El Salvador
infection, neutralized all five clones, we found a 9-fold difference
(P,0.05) between the calculated lowest and highest neutralizing
titers, with a low neutralizing group consisting of Indonesia ’82 (I),
1:133, and PR ’77 (IV) 1:157 and a second, high neutralizing
group included the remaining clones Cuba ’02 - 1:701, Thailand
Table 1. Mean focus size for parent virus and chimeric clones.
Clone focus diameter (mm)* 95% CI
SL ’89 (parent virus) 1.09 1.04–1.15
SL ’89 (arent clone) 1.03 0.91–1.15
Indonesia ’82 (I) 0.92 0.85–0.99
Thailand ’95 (II) 0.84 0.72–0.96
Cuba ’02 (III) 1.09 0.97–1.21
Puerto Rico ’77 (IV) 0.73 0.66–0.80
*At least 30 foci were measured for each clone.
doi:10.1371/journal.pntd.0001486.t001
Figure 2. Phylogenetic relationship of DENV-3 viruses. The phylogenetic tree illustrates genetic relatedness of DENV-3 virus genotypes,
including those viruses from which representative E genes were synthesized. This tree is meant to display DENV-3 diversity but does not include all
175 sequences used to evaluate the genetic variability of the DENV-3 E gene. Instead, representative sequences from each genotype were selected
for inclusion in the tree. The tree was constructed using Maximum Likelihood method based on the Tamura-Nei model [66]. The tree is drawn to
scale, with branch lengths measured in the number of substitutions per site. The analysis involved 37 nucleotide sequences. There were a total of
1479 positions in the final dataset. Evolutionary analyses were conducted in MEGA4 [67]. *Parent virus for E gene variants.
doi:10.1371/journal.pntd.0001486.g002
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(Figure 4D), from an infection in India, was similarly potent, with
four of the five clone titers greater than 1:780, but with the PR ’77
(IV) recombinant virus again showing a significantly lower neu?-
tralization titer at 1:304 (Text S1). Against samples 105 (Figure 4F)
and 118 (Figure 4G), from infections in Thailand and Nicaragua
respectively, the neutralization titers differed five (105) and six
(118) –fold between recombinant viruses expressing Thailand ’95
or PR ’77 E glycoprotein (P,0.05)(Text S1). The most extreme
neutralization differences between the clones were seen using
serum 109 (Figure 4F), from a Sri Lanka donor. This serum, with
titers of 1:177 and 1:280, efficiently neutralized the Indonesia ’82
and Thailand ’95 clones respectively, while the genotype III clones
were neutralized at much lower dilutions of 1:40 (Sri Lanka) and
1:15 (Cuba) (Text S1). Thus, we observed significant variation in
neutralization across DENV-3 genotypes for five of the eight
primary homotypic sera tested.
Human anti DENV secondary sera are known to be broadly
neutralizing across serotypes, and we would expect it to show
relatively high and broad FRNT50 values and resist intra-
genotypic variability. To test this assumption, each of the five
clones were tested against 009, serum from a patient who had a
secondary DENV infection, in India or Sri Lanka in 2000. All of
the clones were efficiently neutralized at relatively high titers,
though the highest (Indonesia ’82) and lowest (Cuba ’02) did differ
significantly (Text S1, Figure 4H), though this difference was less
than three-fold.
Heterotypic primary anti-DENV serum may have low-level
serotype-cross neutralizing activity, and in one study was shown
to be protective for heterotypic infection in some cases [48]. To
assess the role of E glycoprotein variation in heterotypic cross-
neutralization, the clone panel was tested against representative
primary anti-DENV-1, -2, and -4 sera (Table 2, Text S1). Sample
001 was collected after a primary DENV-2 infection acquired in
Sri Lanka in 1996. 001 had low level but detectable FRNT50s that
ranged from 1:11 to 1:78 (Figure 5A, Text S1). Serum 006
FRNT50 titers ranged from 1:7 to 1:54 (Figure 5B, Text S1), and
sample 102, collected after a DENV-4 infection in Honduras, had
a similarly scaled FRNT50 range of 1:12 to 1:58 (Figure 5C, Text
S1). However, while repeat FRNT against the clone panel with
homotypic sera yielded highly reproducible neutralization titers,
repeat FRNTs were not reproducible for heterotypic sera (Text
S1), significantly limiting any conclusions that might be drawn
from variable heterotypic neutralization.
Discussion
CJ Lai et al. described the first full-length infectious DENV
clone for DENV-4 isolate 814669 (isolated from a patient in the
Dominican Republic in 1981 [49]) in 1991 [46]. At that time, the
authors noted the full-length DENV cDNA was unstable in E. coli.
This was overcome by using a two-fragment system that divided
the toxic genomic regions. Subsequent DENV-2 New Guinea C
[45] and DENV-4 West Pacific ’74 clones [44] employed similar
fragment based strategies to overcome genomic stability problems,
though a single plasmid DENV-2 clone has also seen considerable
use ([50–52] for examples).
Table 2. Summary of human primary homotypic, primary
heterotypic and secondary sera used to in neutralization
experiments.
Serum
Infecting
Serotype Location
Year
infected
Year
collected
003 DENV-3 Thailand 2001 2005
005 DENV-3 Puerto Rico 2000 2005
011 DENV-3 El Salvador 1998 2005
033 DENV-3 India 2005 2009
103 DENV-3 Nicaragua 1995 2009
105 DENV-3 Thailand 2002 2009
109 DENV-3 Sri Lanka ND 2010
118 DENV-3 Nicaragua 2008 2010
009 Secondary India and Sri Lanka 2000 2005
006 DENV-1 endemic areas* 1992 2005
031 DENV-2 South Pacific 1997 2005
102 DENV-4 Honduras 2007 2009
Infecting serotype was previously determined by PRNT against reference WHO
strains DENV1 WestPac-74, DENV2 S-16803, DENV3 CH-53489, and DENV4 TVP-
360 (Text S1). Location and year refer to where and when the traveler acquired
the DENV infection. Serum is the patient identifier. ND=No data.
*Endemic areas included Latin America, South Asia and Southeast Asia.
doi:10.1371/journal.pntd.0001486.t002
Figure 3. Recombinant dengue virus growth kinetics in tissue culture. Vero (figure 3A) and C6/36 (figure 3B) cells were inoculated at a
multiplicity of infection (m.o.i) of 0.01 FFU. Cell culture supernatants were harvested at indicated times and the virus released from the infected cells
was quantitated by immunofocus assay. Points show geometric mean titer (GMT) calculated from triplicate titrations. Error bars indicate 95%
confidence intervals for each GMT. For Vero cells no focus forming units were observed at 0 hrs and for C6/36 cells no focus forming units were
observed at 0 hrs and 24 hrs.
doi:10.1371/journal.pntd.0001486.g003
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described the first, and, until now, only, DENV-3 infectious clone
in 2004 [53]. Though based on a full-length cDNA plasmid,
successful propagation of the plasmid DNA required inserting a
30 nt linker region containing termination sequences in each of
the forward and reverse open reading frames near the E/NS1
junction. To date, the parent Sleman ’78 clone has principally
been used as a backbone for vaccine candidates [43,54,55].
Figure 4. Mean FRNT50 values for homotypic primary and secondary sera. Homotypic primary (anti DENV-3) sera (Figures 4A–4H) or
secondary serum (Figure 4I) FRNT50 titers against each of the E variant isogenic clones. Each serum sample is identified above the graph. Serum
histories are summarized in Table 2 and Text S1. Fold-dilution of serum is on the Y-axis and each clone is identified on the X-axis. Columns show GMT
FRNT50 values calculated from FRNT done in triplicate. Error bars indicate 95% confidence intervals. Columns connected by horizontal lines indicate
groups of clones that did not have statistically significantly different FRNT50 values (P,0.05). Connecting bars indicate individual or groups of clones
that differed statistically (P,0.05) by Tukey’s HSD. Sera 003 (Figure 4A), 005 (Figure 4B) and 103 (Figure 4E) did not have significantly different titers
against the recombinant viruses.
doi:10.1371/journal.pntd.0001486.g004
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challenges of developing tractable DENV infectious clones. The
smaller DENV cDNA sub-clone platform we employ offers several
advantages. The individual fragments are highly stable in E coli
and they can be manipulated individually without affecting distant
sites on the genome and allow for fragment re-assortment between
DENV strains. The type IIS restriction enzymes BglI and BsmbI
generates unique 59 and 39 overhangs and prevents spurious self-
assembly of the sub-clones, a technical problem with all pali-
ndromic cutting restriction enzymes [56]. Finally, multiple mu-
tations can be incorporated simultaneously into separate frag-
ments, circumventing iterative mutation and sequencing of the
entire molecular clone and allowing for reassortment of fragments.
With the exception of the genotype I E gene, the parent
molecular clone backbone was receptiveto heterotypic E sequences.
We suspected that genotype specific prM/M-E interactions
between the genotype III parent prM/M and genotype I E
accounted for failure to recover viable genotype I E chimera.
Genotype I prM/M differs from genotype II, III, and IV in 2
positions. The first is a histidine to lysine mutation at prM/M
position 55. This region is predicted to form a strand between two
parallel beta sheets that interacts with the E fusion loop [47] and the
polymorphism at position 55 likely explains why the original
genotype Iclonewasnotviable.Theseconddifferencewas aleucine
to phenylalanine mutation at position 128. This polymorphism
conserves the hydrophobic character of the residue, hence we think
it unlikely that this mutation affected the original genotype I
chimera’s viability. Replacing the parent prM gene with a genotype
I prM established a viable clone and argues that future constructs
should include prM and E from the same genotype. However,
overall, the clone platform was remarkably stable: full length
sequencing of passage three of all five of the clones found only one
(silent) nucleotide mutation in one - Indonesia ’82 - of the five
clones. The recombinant viruses grew to equivalent peak titers
compared to the parent clone, though Indonesia ’82 showed
delayed growth kinetics in both cell lines. Different plaque
phenotypes emerged with E glycoprotein changes. While chimeric
construction may affect interactions between E and the non-
structural proteins or directly change RNA-RNA interactions, these
effects are likely subtle, given the relatively similar clone growth
kinetics in tissue culture, and are unlikely to directly affect chimeric
clone neutralization by polyclonal sera.
Forty years ago Halstead and others first reported variable
neutralization between clinical DENV-3 isolates [57] when they
observed that mouse immune sera raised against DENV-3 strain
H-87 poorly neutralized low passage wild-type DENV-3 isolates
from Thailand. The authors hypothesized that the observed
differences in neutralization were due to within serotype antigenic
differences. Shortly thereafter, Russell et al. reported similar
findings for human immune sera [58]. They found that both
human convalescent sera and mouse hyper-immune sera against
Tahitian and Caribbean DENV-3 poorly neutralized H-87 and a
Thailand 1965 clinical isolate with differences in 50% hemagglu-
tination inhibition (HI) titers varying by more that 10-fold. The
authors argued that the different titers were evidence of genetic
subtypes within DENV-3, at the time a novel idea, although the
genetic basis for this variable phenotype was unclear. The authors
also argued that Caribbean strains would be poor vaccine
candidates because of their antigenic properties did not elicit
broadly neutralizing homotypic antibodies. Despite this early
observation of variable neutralization within serotypes, the phe-
nomenon remained largely unexplored, in part because few tools
existed to isolate antigenic variation in an otherwise stable genetic
background.
More recently, Zulueta et al. [22], found that human sera from
acute genotype III DENV-3 infections were essentially non-
reactive with recombinant genotype IV EDIII but appropriately
reactive with genotype III EDIII. However, this study’s findings
were significantly limited by the use of pooled acute human sera
and binding assays, rather than neutralization assays and
individual human polyclonal serum samples. In a related set of
experiments, Cuban researchers tested convalescent sera collected
from twenty DF and DHF cases from the 2001/2002 Cuban
DENV-3 epidemic against a panel of six DENV-3 isolates
collected between 2000 and 2002 [19]. The sera PRNT50 titers
against clinical isolates from before and after that epidemic
differed by nearly 10-fold, with the patients’ sera more effectively
neutralized virus from after the epidemic than before. However,
Figure 5. Mean FRNT50 values for heterotypic primary sera. Each serum sample is identified above the graph. Serum 001(Figure 5A) is from a
primary DENV-2 infection in; Serum 006 (Figure 5B) is from a primary DENV-1 infection; Serum 102 (Figure 5C) is from a primary DENV-4 infection.
Serum histories are summarized in Table 2 and Text S1. Fold-dilution of serum is on the Y-axis and each clone is identified on the X-axis. Columns
show GMT FRNT50 values calculated from FRNT done in triplicate.
doi:10.1371/journal.pntd.0001486.g005
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type viruses representing only genotypes III and IV and only three
of the seven viruses used were sequenced. Finally, Thomas et al.
[59], using previously characterized human DENV sera, found
that PRNT50 titers were significantly affected by both virus strain
and tissue in which the virus was propagated. While these
experiments strongly hint at E gene dependent differences in
polyclonal antibody neutralization, they do not directly test
variability in the neutralization of isogenic DENV-3 viruses
encoding clearly defined E gene differences by late convalescent
sera.
Our results significantly advance both the pioneering early
studies of Halstead and Russell as well as the more recent work
cited above, all of which collectively argue that antigenic
variability in DENV-3 genotypes significantly influences intra-
serotypic neutralization responses in in vitro assays. With our panel
of sera and E variant clones, we found both dramatically large, up
to 19-fold, differences in FRNT50 values and FRNT50 titers as low
as 1:15 for homotypic sera (Text S1). Our data indicate that
variation in E strongly drives these phenotypes, as all other viral
proteins were isogenic.
Prospective studies of DENV transmission have found that low
titer pre-existing neutralizing Ab (by PRNT) in endemic areas does
not uniformly protect from homotypic infection [24], and a
prospective study of maternal antibody in newborns found that
50% neutralization titers of ,1:50 are often not protective against
homologous virus strains, even in endemic settings [60]. Finally, a
recent human challenge study in DENV-3 vaccinated subjects
found that a PRNT titer 1:57 in one vaccinated volunteer was only
partially protective, and another volunteer developed both fever
and viremia with a pre-existing anti-DENV-3 titer of 1:16 [61].
Current vaccine trials define 50% or 60% neutralization titers of
.1:10 [62,63] or 1:20 as evidence of immunity, potentially lower
than the hypothesized protective thresholds suggested by the
studies cited above. Some recent vaccine studies by Durbin et al.
Guy et al. have begun to test vaccinee sera against representative
genotypes [64,65]. However, Durbin et al. used early convalescent
sera - 42 days post vaccination, which is likely to be more broadly
neutralizing is too early post-vaccination to capture the durable,
long-term antibody response. Guy et al. similarly evaluated
vaccinated vaccine sera against DENV genotypic variants, but
used primate rather than human sera and the authors did not
specify when the samples were collected post vaccination. The
magnitude of the neutralization differences we report may be
enough to lead to partial protection or loss of protection in
vaccines, depending on the infecting genotype. It is also possible
that, in the context of live virus vaccination, broad within serotype
protection is conferred even with low titer antibodies, and that
genotypic differences will not matter in the context of protection.
That said, Genotype IV stands out in our experiments as relatively
non-reactive with homotypic human immune sera (Figure 4B, 4E,
4F) and raises the question of whether vaccination could
potentially create an immunologic ‘‘niche’’ in human hosts that
could be exploited by sylvatic or geographically and genetically
distant genotypes within a serotype.
Our findings serve as a point of departure for studying the
important epitopes in the human antibody response to DENV
infection, most of which have not yet been defined. Clones that
selectively alter the antigenic clusters distributed across E (Text S1)
will facilitate initial mapping of the epitopes responsible for
differential neutralization. Ideally, identifying the key neutralizing
epitopes in the human polyclonal immune response will, in turn,
inform rational vaccine and possibly therapeutic monoclonal
antibody design - optimizing epitopes to elicit potent neutralizing
antibodies. Although only speculative, the DEN3 molecular clone
may also prove invaluable for identifying epitopes and antibodies
responsible for enhancing dengue infection.
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